Julio Raúl Fernández Massó

Dr. Julio Raúl Fernández Massó

Center for Genetic Engineering and Biotechnology
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Life Sciences
Verified
Journal Article
Closed access
MCMajel Cervantes-Llanos
Majel Cervantes-Llanos
NLNielsen Lagumersindez-Denis
Nielsen Lagumersindez-Denis
JMJavier Marín-Prida
Javier Marín-Prida
NPNancy Pavón-Fuentes
Nancy Pavón-Fuentes
VFViviana Falcon-Cama
Viviana Falcon-Cama
GPGiselle Pentón-Rol
Giselle Pentón-Rol

1 October 2013 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
JMJavier Marín-Prida
Javier Marín-Prida
NPNancy Pavón-Fuentes
Nancy Pavón-Fuentes
ALAlexey Llópiz-Arzuaga
Alexey Llópiz-Arzuaga
JMJulio Raúl Fernández Massó
Julio Raúl Fernández Massó
LDLiván Delgado-Roche
Liván Delgado-Roche
GPGiselle Pentón-Rol
Giselle Pentón-Rol

1 January 2006 in Neuroscience Letters
Verified
Journal Article
Closed access
JAJorge Agustín Aguiar
Jorge Agustín Aguiar
JMJulio Raúl Fernández Massó
Julio Raúl Fernández Massó
AAAnselmo Aguilar
Anselmo Aguilar
YMYssel Mendoza-Marí
Yssel Mendoza-Marí
MVMaría Vázquez
María Vázquez
NMNelson Merino
Nelson Merino

16 January 2013 in Journal of Amino Acids
Verified
Journal Article
Open access
PDF file
JMJulio Raúl Fernández Massó
Julio Raúl Fernández Massó
BABrizaida Oliva Argüelles
Brizaida Oliva Argüelles
YTYelaine Tejeda
Yelaine Tejeda
SASoledad Astrada
Soledad Astrada
HGHilda Garay
Hilda Garay
MVMaribel G. Vallespí
Maribel G. Vallespí
We have demonstrated that the peptide L-2 designed from an alanine scanning of theLimulus-derived LALF32-51 region is a potential candidate for the anticancer therapy and its cell-penetrating capacity is an associated useful property. By the modification in the primary structure of L-2, a second-generation peptide (CIGB-552) was developed. However, the molecular mechanism underlying its cytotoxic activity remains partially unknown. In this study, it was shown that CIGB-552 increases the levels of COMMD1, a protein involved in copper homeostasis, sodium transport, and the NF-κB signaling pathway. We found that CIGB-552 induces ubiquitination of RelA and inhibits the antiapoptotic activity regulated by NF-κB, whereas the knockdown of COMMD1 blocks this effect. We also found that CIGB-552 decreases the antioxidant capacity and induces the peroxidation of proteins and lipids in the tumor cells. Altogether, this study provides new insights into the mechanism of action of the peptide CIGB-552, which could be relevant in the design of future anticancer therapies.

10 November 2015 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
GPGiselle Pentón-Rol
Giselle Pentón-Rol
NLNielsen Lagumersindez-Denis
Nielsen Lagumersindez-Denis
LMLuca Muzio
Luca Muzio
ABAlessandra Bergami
Alessandra Bergami
RFRoberto Furlan
Roberto Furlan
EPEduardo Pentón-Arias
Eduardo Pentón-Arias

11 November 2009 in Journal of Peptide Science
Verified
Journal Article
Closed access
PDF file
MVMaribel G. Vallespi
Maribel G. Vallespi
JMJulio Raúl Fernández Massó
Julio Raúl Fernández Massó
ITIsis Torrens
Isis Torrens
IGIsbel Garcia
Isbel Garcia
HGHilda Garay
Hilda Garay
OROsvaldo Reyes
Osvaldo Reyes